TAINAN, Taiwan, Aug. 31 /PRNewswire-Asia/ -- ScinoPharm, a leading active pharmaceutical ingredient (API) developer and manufacturer headquartered in Taiwan, today announced an investment into Tanvex Biologics, Inc., a United States company registered in the State of Delaware. ScinoPharm's investment was in the form of tangible assets, intellectual properties, as well as cash.
Tanvex specializes in the development of biosimilars and biobetters, as well as the provision of contract research and contract manufacturing services for biologics. The company is currently establishing a cGMP facility in San Diego, California and will have research centers in both the U.S. and Taiwan. Tanvex is founded by Dr. Allen Chao, the founder and former Chairman and Chief Executive Officer of Watson Pharmaceuticals, Inc.
Dr. Hardy Chan, co-founder and Chief Scientific Officer of ScinoPharm, will become the Chief Executive Officer of Tanvex. Dr. Chao will remain as Executive Chairman of Tanvex.
About ScinoPharm Taiwan
ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and mainland China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. For more information, please visit http://www.scinopharm.com .
About Tanvex Biologics
Tanvex Biologics, LLC is a US-based biopharmaceutical company specializing in the development of biopharmaceuticals.
Media Contact: ScinoPharm Taiwan, Ltd. Sabrian Wu Tel: +886-6-505-2869 Mobile Phone: +886-920-056-385 Email: email@example.com
|SOURCE ScinoPharm Taiwan, Ltd.|
Copyright©2010 PR Newswire.
All rights reserved